近2亿！上海国资，投了一家AI4S，打造“生命世界模型”
Ranking
Overall
40
Content
35
Popularity
N/A
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - Beijing-based AI4S company Zheyuan Technology (哲源科技) raised nearly ¥200M in an A2 round led by Sansure Biotech's industry fund, with Shanghai state-backed Zhangjiang Sci-Tech among co-investors, to scale its "Life World Model" platform for drug discovery.
- The platform builds a "digital twin of life function," integrating multi-omics, cell-experiment, pathology and clinical data into an AI-navigable substrate.
- Five model families: biomedical knowledge model, population/individual dual-scale genomic language model, signaling-pathway model, virtual cell model, and lesion world model — spanning genetic analysis to lesion-evolution simulation.
- Two commercial offerings: D2P (Disease to Product, full-cycle co-development with pharma from target discovery to launch) and T2I (Target to Indication, digital-twin simulated trials to pinpoint indications and benefiting patient populations).
- In-house Class I drug PR00012 has entered Phase I; collaborations with national medical centers target oncology and psychiatric diseases for novel target discovery.
Sources (1)
近2亿！上海国资，投了一家AI4S，打造“生命世界模型”
Public signals
N/A
TL;DR - Beijing-based AI4S company Zheyuan Technology (哲源科技) raised nearly ¥200M in an A2 round led by Sansure Biotech's industry fund, with Shanghai state-backed Zhangjiang Sci-Tech among co-investors, to scale its "Life World Model" platform for drug discovery.
- The platform builds a "digital twin of life function," integrating multi-omics, cell-experiment, pathology and clinical data into an AI-navigable substrate.
- Five model families: biomedical knowledge model, population/individual dual-scale genomic language model, signaling-pathway model, virtual cell model, and lesion world model — spanning genetic analysis to lesion-evolution simulation.
- Two commercial offerings: D2P (Disease to Product, full-cycle co-development with pharma from target discovery to launch) and T2I (Target to Indication, digital-twin simulated trials to pinpoint indications and benefiting patient populations).
- In-house Class I drug PR00012 has entered Phase I; collaborations with national medical centers target oncology and psychiatric diseases for novel target discovery.